ClinicalTrials.gov record
Completed Phase 1 Interventional

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00012207

Public ClinicalTrials.gov record NCT00012207. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 9:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study To Evaluate The Safety Of Cellular Immunotherapy Using Genetically Modified Autologous Cd20-Specific Cd8+ T Cell Clones For Patients With Relapsed Cd20+ Indolent Lymphomas

Study identification

NCT ID
NCT00012207
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Fred Hutchinson Cancer Center
Other
Enrollment
12 participants

Conditions and interventions

Interventions

  • adjuvant therapy Procedure
  • aldesleukin Biological
  • cyclophosphamide Drug
  • prednisone Drug
  • therapeutic autologous lymphocytes Biological
  • vincristine sulfate Drug

Procedure · Biological · Drug

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2000
Primary completion
Not listed
Completion
Jun 30, 2010
Last update posted
Aug 23, 2010

2000 – 2010

United States locations

U.S. sites
3
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
City of Hope Comprehensive Cancer Center Duarte California 91010-3000
Fred Hutchinson Cancer Research Center Seattle Washington 98109-1024
University of Washington School of Medicine Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00012207, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 23, 2010 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00012207 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →